3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
5016
Carcinoma, Renal Cell
1574
Urinary Bladder Neoplasms
1279
Kidney Neoplasms
723
Breast Neoplasms
642
Neoplasms
628
Carcinoma, Transitional Cell
487
Neoplasm Metastasis
468
Carcinoma, Non-Small-Cell Lung
467
Melanoma
421
Ovarian Neoplasms
399
Colorectal Neoplasms
370
Lung Neoplasms
333
Pancreatic Neoplasms
262
Sarcoma
231
Stomach Neoplasms
226
Uterine Cervical Neoplasms
223
Testicular Neoplasms
215
Non-Muscle Invasive Bladder Neoplasms
214
Head and Neck Neoplasms
192
Squamous Cell Carcinoma of Head and Neck
187
Colonic Neoplasms
167
Carcinoma, Hepatocellular
165
Esophageal Neoplasms
164
Endometrial Neoplasms
164
Wilms Tumor
159
Recurrence
131
Triple Negative Breast Neoplasms
128
Neuroblastoma
127
Small Cell Lung Carcinoma
125
Interventions
darolutamide
2
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Biochemically Recurrent Prostate Cancer
×
Genitourinary
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts